BioCentury
ARTICLE | Clinical News

PhaseBio's PB2452 reverses antiplatelet activity of Brilinta in Phase I

October 5, 2018 8:31 PM UTC

PhaseBio Pharmaceuticals Inc. (Malvern, Pa.) said PB2452 (formerly MEDI2452) rapidly and completely reversed the antiplatelet activity of cardiovascular drug Brilinta ticagrelor from AstraZeneca plc (LSE:AZN; NYSE:AZN) in a Phase I trial. The company is developing PB2452 to reverse the antiplatelet activity of Brilinta in patients who are experiencing a major bleeding event or who require urgent surgery.

The double-blind, dose-escalation, U.S. trial enrolled 45 healthy volunteers with or without Brilinta pretreatment to receive placebo or a single infusion of PB2452...